Immune cell therapy for hard-to-treat myasthenia gravis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new immune cell treatment (CAR T-cells) for people with generalized myasthenia gravis that has not improved with standard treatments. It aims to reduce symptoms by targeting and calming the immune system's attack on muscles.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have generalized myasthenia gravis that is considered refractory (not well controlled by usual treatments)
- Your symptoms are moderate to severe (based on a standard score)
- You have tested positive for certain antibodies (AChR or MuSK)
- You have not had certain prior treatments recently, like IVIG, plasmapheresis, or rituximab
- You do not have active infections, serious heart or lung disease, or certain other conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
This trial is testing a new type of cell therapy called CAR-T that targets two proteins (CD19 and BCMA) on certain immune cells. It aims to help people with severe myasthenia gravis that has not improved with standard treatments.
This trial tests an experimental therapy using special immune cells (UCAR T-cells) to target and destroy certain B cells that produce the antibodies causing myasthenia gravis. It's for people whose symptoms are not well controlled by standard treatments and may offer a new option.
This trial tests a new cell therapy called anitocabtagene autoleucel (anito-cel) for people with generalized myasthenia gravis (gMG) that is not well controlled with current treatments. The goal is to see if it can reduce symptoms and improve quality of life.
This trial tests a new drug called telitacicept combined with low-dose steroids for people with myasthenia gravis that hasn't improved with standard treatments. It aims to reduce muscle weakness and improve daily function.
This early-phase trial tests a new type of immune cell therapy (CAR-T) designed to target and calm the immune system in people with certain autoimmune neurological diseases that haven't improved with standard care. The goal is to see if it's safe and if it can reduce disease activity.
Hear when a new Myasthenia Gravis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.